The Scleral Contact Lenses market has shown robust growth over the past decade, driven by rising prevalence of keratoconjunctivitis, keratoconus, and other corneal disorders. In 2022, the global market was valued at USD 890 million, up from USD 810 million in 2021, reflecting a year-over-year increase of 9.9%. North America dominated with USD 380 million, accounting for 42.7% of total revenue, while Europe contributed USD 290 million, fueled by growing awareness and adoption of specialty lenses in ophthalmology clinics.

From 2014 to 2022, the market grew from USD 480 million to USD 890 million, registering a compound annual growth rate (CAGR) of 8.3%. Particularly strong growth occurred between 2018 and 2021, with year-over-year growth averaging 11.1%, driven by advanced lens designs and increased insurance coverage. Global investment in scleral lens R&D rose from USD 42 million in 2017 to USD 78 million in 2022, reflecting heightened interest from both manufacturers and clinical research institutions.

Regional Market Insights

North America remains the largest regional market, generating USD 380 million in 2022 and projected to reach USD 830 million by 2032 at a CAGR of 8.9%. The U.S. alone contributed USD 320 million, with federal allocations of USD 60 million in 2021 for corneal disease diagnostics and management. Europe accounted for USD 290 million in 2022, led by Germany, France, and the U.K., and is forecasted to grow at 9.5% CAGR to USD 620 million by 2032.

Asia-Pacific has emerged as a rapidly growing market, increasing from USD 45 million in 2015 to USD 110 million in 2022, reflecting a CAGR of 13.6%. Japan and South Korea lead in clinical adoption, with Japan contributing USD 55 million in 2022. By 2032, Asia-Pacific is projected to reach USD 370 million, driven by rising keratoconus prevalence, increased disposable income, and expanding optometry infrastructure.

Product Segment Analysis

Rigid gas-permeable scleral lenses dominated revenue in 2022, contributing USD 520 million (58% of global revenue). Hybrid lenses accounted for USD 210 million, while soft scleral lenses contributed USD 160 million. Rigid gas-permeable lenses are projected to grow at a CAGR of 10.3% from 2023–2032, reaching USD 1.2 billion. Hybrid and soft lenses are expected to grow at 11.2% and 10.7% CAGR, respectively, as more patients seek comfort combined with visual acuity.

Application Insights

Scleral contact lenses are primarily used for keratoconus, post-surgical corneal irregularities, and severe dry eye disease. In 2022, keratoconus accounted for USD 480 million (54% of total revenue), growing from USD 420 million in 2021 (14.3% growth). Post-surgical corneal irregularities generated USD 230 million, with a 12.5% annual increase from USD 205 million in 2021. Severe dry eye applications contributed USD 180 million, up from USD 165 million in 2021, reflecting the rise in ophthalmic complications among aging populations.

Historical Data and Yearly Comparisons

  • 2014: Market size USD 480 million, North America USD 210 million
  • 2016: Market USD 550 million, Asia-Pacific USD 38 million
  • 2018: Market USD 670 million, Europe USD 210 million
  • 2020: Market USD 780 million, global R&D investment USD 65 million
  • 2022: Market USD 890 million, North America USD 380 million, Asia-Pacific USD 110 million

This historical data shows a consistent upward trajectory with a seven-year CAGR of 8.3%, reflecting steady adoption across mature and emerging markets.

Key Market Players and Industry Statistics

Prominent companies in the scleral contact lenses market include Bausch + Lomb, Contamac Ltd., and Blanchard Contact Lens. Bausch + Lomb invested USD 42 million in R&D in 2022, while Contamac allocated USD 28 million. Combined production volumes exceeded 1.35 million units in 2022, up from 980,000 units in 2020, reflecting increasing clinical adoption.

Market Drivers and Statistical Highlights

The rising prevalence of keratoconus is a key growth driver, increasing from 1:2,000 in 2014 to 1:1,750 in 2022, a 14% rise. Survey data indicates that 63% of ophthalmologists plan to expand scleral lens fitting programs over the next five years. Production volumes of rigid gas-permeable lenses increased from 620,000 units in 2019 to 780,000 units in 2022. Revenue growth among top players is substantial: Bausch + Lomb reported USD 180 million in 2022, up 16% from USD 155 million in 2021.

Future Projections

The global scleral contact lenses market is projected to reach USD 1.9 billion by 2032, with a CAGR of 10.9% from 2023–2032. North America will remain the largest market at USD 830 million, Europe will reach USD 620 million, and Asia-Pacific is forecasted at USD 370 million. Rigid gas-permeable lenses will remain the dominant segment, while hybrid and soft scleral lenses will see faster growth in emerging regions.

Investments in R&D and government healthcare funding are projected to exceed USD 150 million by 2030, supporting clinical trials and product innovations. Keratoconus and post-surgical applications will continue to dominate, contributing 65% of total market revenue by 2032, while severe dry eye applications will grow steadily at 10.8% CAGR.

Conclusion

The scleral contact lenses market demonstrates strong double-digit growth, from USD 890 million in 2022 to USD 1.9 billion by 2032, with a CAGR of 10.9%. North America and Europe remain mature markets, while Asia-Pacific shows the fastest growth. Rigid gas-permeable lenses dominate revenue, followed by hybrid and soft lenses. Rising keratoconus prevalence, increased clinical adoption, and robust R&D investments make scleral contact lenses a high-growth segment in ophthalmology.

Read Full Research Study: Scleral Contact Lenses https://marketintelo.com/report/scleral-contact-lenses-market